LB3439 - ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN UNTREATED MANTLE CELL LYMPHOMA: RESULTS FROM THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED ECHO TRIAL

LB3444 - VITAMIN C SUPPLEMENTATION IN PATIENTS WITH CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE OR LOW-RISK MYELOID MALIGNANCIES: RESULTS FROM EVI-2, A RANDOMIZED, PLACEBO-CONTROLLED PHASE 2 STUDY

S164 - COMBINED PIRTOBRUTINIB, VENETOCLAX, AND OBINUTUZUMAB IN FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PHASE 2 TRIAL

LB3438 - GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (GLOFIT-GEMOX) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS OF A GLOBAL RANDOMIZED PHASE III TRIAL (STARGLO)

S204 - DARATUMUMAB (DARA) + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) FOLLOWED BY DARA MAINTENANCE IN TRANSPLANT-ELIGIBLE (TE) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): >6-YEAR UPDATE OF CASSIOPEIA

S239 - FIRST DATA FROM SUBCUTANEOUS EPCORITAMAB+POLATUZUMAB VEDOTIN, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA-R-CHP) FOR FIRST-LINE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): EPCORE NHL-5

S225 - THE RANDOMIZED STUDY GHSG HD21 SHOWS SUPERIOR TOLERABILITY AND EFFICACY OF BRECADD VERSUS BEACOPP IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA

S222 - EFFICACY AND SAFETY OF NAVITOCLAX IN COMBINATION WITH RUXOLITINIB VERSUS RUXOLITINIB PLUS PLACEBO IN PATIENTS WITH UNTREATED MYELOFIBROSIS IN THE PHASE 3 RANDOMIZED, DOUBLE-BLIND TRANSFORM-1 STUDY

S102 - FIRST RESULTS OF THE APOLLO TRIAL: A RANDOMIZED PHASE III STUDY TO COMPARE ATO COMBINED WITH ATRA VERSUS STANDARD AIDA REGIMEN FOR PATIENTS WITH NEWLY DIAGNOSED, HIGH-RISK ACUTE PROMYELOCYTIC LEUKEMIA

S207 - PHASE 1 STUDY OF ANITOCABTAGENE AUTOLEUCEL FOR THE TREATMENT OF PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA: RESULTS FROM AT LEAST 1-YEAR FOLLOW-UP IN ALL PATIENTS

LB3442 - ELA026 TARGETING OF SIRP(+) IMMUNE CELLS RESULTS IN A HIGH RESPONSE RATE AND IMPROVED 2-MONTH SURVIVAL OF TREATMENT-NAIVE MALIGNANCY-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PHASE 1 STUDY

S163 - SINGLE-AGENT EPCORITAMAB LEADS TO DEEP RESPONSES IN PATIENTS (PTS) WITH RICHTER'S TRANSFORMATION (RT): PRIMARY RESULTS FROM THE EPCORE CLL-1 TRIAL

S201 - DARATUMUMAB + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: ANALYSIS OF MINIMAL RESIDUAL DISEASE IN THE PERSEUS TRIAL

S142 - QUANTUM-FIRST: EFFICACY IN NEWLY DIAGNOSED PATIENTS WITH FMS-LIKE TYROSINE KINASE 3-INTERNAL TANDEM DUPLICATION–POSITIVE (FLT3-ITD+) ACUTE MYELOID LEUKEMIA (AML) WHO RECEIVED CONTINUATION THERAPY

S237 - ENGLUMAFUSP ALFA (CD19/4-1BBL) COMBINED WITH GLOFITAMAB IS SAFE AND SHOWS HIGH EFFICACY IN PATIENTS WITH R/R AGGRESSIVE B-NHL: FINAL RESULTS OF THE DOSE-ESCALATION PART OF PHASE1 TRIAL BP41072